Novo Nordisk to cut 9,000 jobs globally
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
PendraCare Group develops, manufactures and sells innovative cardiology catheter solutions and provides design, development and manufacturing services to other global OEM’s
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Subscribe To Our Newsletter & Stay Updated